Moderna Inc. (MRNA)
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
Moderna MRNA incurred a loss of 51 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.15. In the year-ago period, the company had reported earnings per share (EPS) of 3 cents.
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $0.03 per share a year ago.
Moderna Swings to a Loss on Fewer Covid-19 Vaccine Sales
Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
Moderna: Focus On Cancer Vaccines, Not Buyout
Moderna surged on reports of talks with a large biopharma for a potential partnership or buyout, despite trading at multi-year lows. MRNA's promising cancer vaccine data and surprising findings on mRNA Covid vaccines boosting cancer survival rates drive renewed optimism for the drug pipeline. The company maintains a strong cash position, reduced costs, and a robust drug pipeline, with cancer vaccines representing the largest market opportunity.
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.
Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength?
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges
Shares of a social media juggernaut slumped as investors balked at its rapidly accelerating spending on artificial intelligence, while reports of potential partnership or buyout talks helped a vaccine maker's shares shoot higher.
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.
Moderna Vs BioNTech: Who's Winning The Post-COVID Race
Moderna and BioNTech were the main 'saviors' of people and economies from COVID-19. However, since the pandemic ended, their stock prices have fallen by more than 70%. Recognizing this, BioNTech and Moderna continue to actively diversify their portfolios of experimental drugs and vaccines toward cancer treatment.
